Passage BIO, Inc.
Passage Bio, Inc. (Nasdaq: PASG) is a clinical-stage genetic medicines company developing one-time gene therapies for neurodegenerative diseases. Its lead candidate, PBFT02, uses an AAV1 vector to deliver a functional GRN gene and raise progranulin levels in the central nervous system; it is being studied in a Phase… From the company’s description.
In fiscal 2025, Passage BIO, Inc. reported a net loss of $45.52M. Operations used $31.51M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Passage BIO, Inc. does
In the company’s own words
Passage Bio, Inc. (Nasdaq: PASG) is a clinical-stage genetic medicines company developing one-time gene therapies for neurodegenerative diseases. Its lead candidate, PBFT02, uses an AAV1 vector to deliver a functional GRN gene and raise progranulin levels in the central nervous system; it is being studied in a Phase 1/2 trial for frontotemporal dementia caused by GRN mutations and in a trial cohort for FTD associated with C9orf72 mutations. The company is also evaluating PBFT02 for potential use in amyotrophic lateral sclerosis and Alzheimer’s disease. Through a collaboration with Gemma Biotherapeutics, Passage Bio is conducting preclinical research on an AAV-based genetic medicine for Huntington’s disease and may license programs for four additional central nervous system indications. It has sublicensed three pediatric programs previously advanced to clinical development to Gemma. Passage Bio relies on third-party manufacturers for clinical product supply, with internal manufacturing and quality teams overseeing external operations.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- PHILADELPHIA, PA
- Fiscal year end
- December
- CIK
- 1787297
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Passage BIO, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Passage BIO, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Passage BIO, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Passage BIO, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Passage BIO, Inc.'s last four quarterly filings that the numbers alone won't show?”